WMA
VKTX icon

Wealth Management Associates’s Viking Therapeutics VKTX Stock Holding History

Wealth Management Associates’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,545
Closed -$253K – 241
2025
Q2 		$253K Sell
9,545
-430
-4% -$11.3K 0.1% 183
2025
Q1 		$241K Buy
+9,975
New +$315K 0.1% 181

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wealth Management Associates's VKTX Position: Q3 2025 in Review

Wealth Management Associates sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 9,545 shares — an estimated $253K sold.

Wealth Management Associates first reported a position in VKTX in Q1 2025 and held it in 2 quarters. The position peaked at $253K in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Wealth Management Associates reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wealth Management Associates sold 9,545 Viking Therapeutics shares in Q3 2025, an estimated $253K.
  • Wealth Management Associates first reported a position in Viking Therapeutics in Q1 2025 and held it in 2 quarters.
  • Wealth Management Associates's Viking Therapeutics position peaked at $253K in Q2 2025.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Wealth Management Associates's 13F filing for Q3 2025, filed 21 Oct 2025.